Skip to main content
Nicholas Brownell, MD, Cardiology, Los Angeles, CA

NicholasKeisukeBrownellMD(He/Him)

Cardiology Los Angeles, CA

Fellow Physician (PGY-8)

Dr. Brownell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Brownell's full profile

Already have an account?

  • Office

    100 UCLA Medical Plz
    Ste 630
    Los Angeles, CA 90024
    Phone+1 310-825-9011
    Fax+1 310-206-9133

Summary

  • Dr. Nicholas Brownell is a cardiology fellow (PGY-8) at UCLA. He received his medical degree from Emory University School of Medicine and completed his residency in internal medicine at UT Southwestern. He is currently a cardiology research fellow at UCLA David Geffen School of Medicine, where he is also completing a PhD in Health Policy and Management. He has been in practice for 8 years.

Education & Training

  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Cardiovascular Disease, 2019 - 2024
  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Internal Medicine, 2015 - 2018
  • Emory University School of Medicine
    Emory University School of MedicineClass of 2015
  • University of Pennsylvania
    University of PennsylvaniaB.S., Bioengineering, Cum Laude, 2006 - 2010

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2019 - 2025
  • TX State Medical License
    TX State Medical License 2017 - 2020
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Cardiac Arrest: When the Heart Stops, Save Lives with High-Quality CPRSeptember 2023
  • Simultaneous Versus Sequential Initiation of HFrEF TherapiesMarch 2022
  • VERTIS CV Trial: Heterogeneity in Clinical Benefits of Sodium-glucose Cotransporter-2 Inhibitors for Patients with Type II Diabetes?September 2020